48 active not recruiting. 48 Phase 3.
By phase and status
Follow Multiple Myeloma: new trials by email Literature Review of Multiple Myeloma trials Research Report on Multiple Myeloma
Trials (filtered) newest first · largest first
All 48 trials
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|
A Study to Compare Pharmacokinetics, Efficacy and Safety of Subcutaneous CT-P44 and Darzalex Faspro in Combination With Lenalidomide and Dexamethasone in Patients With Refractory or Relapsed Multiple Myeloma
CT-P44(Daratumumab), Darzalex Faspro(Daratumumab) - Refractory or Relapsed Multiple Myeloma | Phase 3 | Active not recruiting | 473 | 2025-08-12 | 2026-10-27 |
A Study Comparing Anitocabtagene Autoleucel to Standard of Care Therapy in Participants With Relapsed/ Refractory Multiple Myeloma
Anitocabtagene Autoleucel, Cyclophosphamide, Fludarabine - Multiple Myeloma | Phase 3 | Active not recruiting | 452 | 2024-08-23 | 2026-07-29 |
Study Assessing Activity of Intravenous (IV) Etentamig Monotherapy Versus Standard Available Therapies in Adult Participants With Relapsed or Refractory Multiple Myeloma
Etentamig, Carfilzomib, Pomalidomide - Multiple Myeloma | Phase 3 | Active not recruiting | 421 | 2024-05-19 | 2026-08-27 |
Iberdomide vs. Iberdomide Plus Isatuximab Maintenance Therapy Post ASCT in Newly Diagnosed Multiple Myeloma
Iberdomide, Isatuximab, Dexamethasone - Multiple Myeloma | Phase 3 | Active not recruiting | 411 | 2024-04-05 | 2026-08-17 |
A Study Comparing Talquetamab Plus Pomalidomide, Talquetamab Plus Teclistamab, and Elotuzumab, Pomalidomide, and Dexamethasone or Pomalidomide, Bortezomib, and Dexamethasone in Participants With Relapsed or Refractory Myeloma Who Have Received an Anti-CD38 Antibody and Lenalidomide
Talquetamab, Pomalidomide, Teclistamab - Multiple Myeloma | Phase 3 | Active not recruiting | 838 | 2024-01-22 | 2026-09-25 |
A Study to Compare the Efficacy and Safety of Idecabtagene Vicleucel With Lenalidomide Maintenance Therapy Versus Lenalidomide Maintenance Therapy Alone in Adult Participants With Newly Diagnosed Multiple Myeloma Who Have Suboptimal Response After Autologous Stem Cell Transplantation
idecabtagene vicleucel, Lenalidomide, Fludarabine - Multiple Myeloma | Phase 3 | Active not recruiting | 79 | 2023-10-16 | 2026-03-05 |
A Study of Daratumumab, Bortezomib, Lenalidomide and Dexamethasone (DVRd) Followed by Ciltacabtagene Autoleucel Versus Daratumumab, Bortezomib, Lenalidomide and Dexamethasone (DVRd) Followed by Autologous Stem Cell Transplant (ASCT) in Participants With Newly Diagnosed Multiple Myeloma
Daratumumab, Bortezomib, Lenalidomide - Multiple Myeloma | Phase 3 | Active not recruiting | 759 | 2023-10-10 | 2026-03-17 |
A Study to Compare Iberdomide Maintenance Versus Lenalidomide Maintenance Therapy Following Autologous Stem Cell Transplant in Participants With Newly Diagnosed Multiple Myeloma
Iberdomide, Lenalidomide - Multiple Myeloma | Phase 3 | Active not recruiting | 1230 | 2023-06-22 | 2026-09-17 |
A Study Comparing Teclistamab Monotherapy Versus Pomalidomide, Bortezomib, Dexamethasone (PVd) or Carfilzomib, Dexamethasone (Kd) in Participants With Relapsed or Refractory Multiple Myeloma
Teclistamab, Pomalidomide, Bortezomib - Relapsed or Refractory Multiple Myeloma | Phase 3 | Active not recruiting | 614 | 2023-03-29 | 2026-04-13 |
A Study to Evaluate Mezigdomide in Combination With Carfilzomib and Dexamethasone (MeziKD) Versus Carfilzomib and Dexamethasone (Kd) in Participants With Relapsed or Refractory Multiple Myeloma (SUCCESSOR-2)
Mezigdomide, Carfilzomib, Dexamethasone - Relapsed or Refractory Multiple Myeloma | Phase 3 | Active not recruiting | 606 | 2023-01-10 | 2026-09-24 |
A Study of Daratumumab
Daratumumab, Carfilzomib, Dexamethasone - Multiple Myeloma | Phase 3 | Active not recruiting | 213 | 2022-12-15 | 2026-09-25 |
Bringing Optimised COVID-19 Vaccine Schedules To ImmunoCompromised Populations (BOOST-IC): an Adaptive Randomised Controlled Clinical Trial
Pfizer Bivalent COVID-19 Vaccine, Moderna Bivalent mRNA vaccine - HIV, Organ Transplantation | Phase 3 | Active not recruiting | 960 | 2022-12-01 | 2025-10-03 |
A Study Comparing Talquetamab in Combination With Daratumumab or in Combination With Daratumumab and Pomalidomide Versus Daratumumab in Combination With Pomalidomide and Dexamethasone in Participants With Multiple Myeloma That Returns After Treatment or is Resistant to Treatment
Talquetamab, Daratumumab, Pomalidomide - Multiple Myeloma | Phase 3 | Active not recruiting | 864 | 2022-10-13 | 2026-09-25 |
Open-label Study Comparing Iberdomide, Daratumumab and Dexamethasone (IberDd) Versus Daratumumab, Bortezomib, and Dexamethasone (DVd) in Participants With Relapsed or Refractory Multiple Myeloma (RRMM)
Dexamethasone, Daratumumab, Bortezomib - Multiple Myeloma | Phase 3 | Active not recruiting | 939 | 2022-06-23 | 2026-04-03 |
A Study of Combination of Selinexor, Pomalidomide, and Dexamethasone (SPd) Versus Elotuzumab, Pomalidomide, and Dexamethasone (EloPd) in Subject With Previously Treated Multiple Myeloma
Selinexor, Elotuzumab, Pomalidomide - Multiple Myeloma | Phase 3 | Active not recruiting | 117 | 2022-04-19 | 2025-12-04 |
Study With Elranatamab Versus Lenalidomide in Patients With Newly Diagnosed Multiple Myeloma After Transplant
Elranatamab, Lenalidomide - Multiple Myeloma | Phase 3 | Active not recruiting | 854 | 2022-03-25 | 2026-04-16 |
All Japanese Population: Belantamab Mafodotin Plus Pomalidomide and Dexamethasone (Pd) Versus Bortezomib Plus Pd in Relapsed/Refractory Multiple Myeloma
Belantamab mafodotin, Pomalidomide, Dexamethasone - Multiple Myeloma | Phase 3 | Active not recruiting | 21 | 2022-02-10 | 2026-06-12 |
MInimal Residual Disease Adapted Strategy
Isatuximab, ASCT - Multiple Myeloma | Phase 3 | Active not recruiting | 791 | 2021-12-08 | 2024-11-07 |
A Study of Teclistamab in Combination With Daratumumab Subcutaneously (SC) (Tec-Dara) Versus Daratumumab SC, Pomalidomide, and Dexamethasone (DPd) or Daratumumab SC, Bortezomib, and Dexamethasone (DVd) in Participants With Relapsed or Refractory Multiple Myeloma
Daratumumab, Pomalidomide, Dexamethasone - Multiple Myeloma | Phase 3 | Active not recruiting | 587 | 2021-10-14 | 2026-09-25 |
A Study of Bortezomib, Lenalidomide and Dexamethasone (VRd) Followed by Cilta-cel, a CAR-T Therapy Directed Against BCMA Versus VRd Followed by Lenalidomide and Dexamethasone (Rd) Therapy in Participants With Newly Diagnosed Multiple Myeloma for Whom ASCT is Not Planned as Initial Therapy
Bortezomib, Dexamethasone, Lenalidomide - Multiple Myeloma | Phase 3 | Active not recruiting | 743 | 2021-08-19 | 2026-09-25 |
Showing 20 of 48. Sign in to see all of them.
Narrower conditions
Recurrence (4) · Lymphoma, Non-Hodgkin (3) · Leukemia, Lymphocytic, Chronic, B-Cell (2) · Neoplasms (2) · Neoplasms, Plasma Cell (2) · Agnosia (1) · Hematologic Diseases (1) · Hodgkin Disease (1) · Leukemia, Myeloid, Acute (1) · Precursor Cell Lymphoblastic Leukemia-Lymphoma (1) · Smoldering Multiple Myeloma (1)
Broader conditions
Blood Protein Disorders (48) · Cardiovascular Diseases (48) · Hemic and Lymphatic Diseases (48) · Hemorrhagic Disorders (48) · Hemostatic Disorders (48) · Immune System Diseases (48) · Immunoproliferative Disorders (48) · Lymphoproliferative Disorders (48) · Neoplasms by Histologic Type (48) · Paraproteinemias (48) · Vascular Diseases (48) · Hematologic Diseases (47) · Neoplasms (46) · Neoplasms, Plasma Cell (46) · Pathological Conditions, Signs and Symptoms (7)
Interventions
Dexamethasone (36) · Bortezomib (23) · Lenalidomide (22) · daratumumab (13) · pomalidomide (13) · carfilzomib (11) · Cyclophosphamide (6) · belantamab mafodotin (6) · isatuximab (6) · Calcium Dobesilate (4) · elotuzumab (4) · fludarabine (4) · Melphalan (3) · Thalidomide (3) · iberdomide (3)
Sponsors
Janssen Research & Development, LLC (7) · GlaxoSmithKline (6) · AbbVie (3) · Bristol-Myers Squibb (2) · Celgene (2) · European Myeloma Network B.V. (2) · National Cancer Institute (NCI) (2) · Sanofi (2) · Stichting European Myeloma Network (2) · University of Arkansas (2) · University of Chicago (2) · University of Heidelberg Medical Center (2) · Assistance Publique - Hôpitaux de Paris (1) · BioLineRx, Ltd. (1) · Celltrion (1)
Countries
United States (33) · Germany (26) · Spain (26) · France (25) · Greece (24) · Italy (23) · Japan (23) · Australia (21) · Belgium (21) · Poland (21) · United Kingdom (20) · South Korea (18) · Canada (17) · China (17) · Czechia (17)
Top investigators
Alexander K Stewart (1) · Amrita Krishnan, MD, FACP (1) · Andrzej Jakubowiak, MD (1) · Andrzej Jakubowiak, MD, PhD (1) · Crees Zachary, MD (1) · Gareth Morgan, MD, PhD (1) · Hartmut Goldschmidt, Prof. (1) · Hartmut Goldschmidt, Prof. Dr. (1) · Hermann Einsele, MD (1) · James H McMahon, MBBS PhD (1)
Results publications
PMID 22689675, PMID 35985959, PMID 40501401, PMID 40763276, PMID 22571201, PMID 22674807, PMID 23305732, PMID 23603914, PMID 26157076, PMID 28826616, PMID 29567784, PMID 31495201, PMID 32866432, PMID 33357481, PMID 33461512, PMID 34549906, PMID 35285981, PMID 35660812, PMID 36328040, PMID 36642080, PMID 37069359, PMID 37272512, PMID 37793771, PMID 37990162, PMID 38052037, PMID 38062124, PMID 38084760, PMID 38573925, PMID 38713888, PMID 38747414, PMID 38828933, PMID 38828951, PMID 38830994, PMID 38832972, PMID 39020446, PMID 39110421, PMID 39234256, PMID 39652594, PMID 39756844, PMID 39841461, PMID 39938094, PMID 40109195, PMID 40171013, PMID 40346992, PMID 40396505, PMID 40459097, PMID 40613875, PMID 40680752, PMID 40680754, PMID 40713834
NIH funding
2023 (10), 2017 (2), 2018 (2), 2019 (2), U10CA021115 (2), U10CA180820 (2), 2016 (1), U10CA031946 (1), U10CA180821 (1), U10CA180888 (1), U24CA196172 (1)